OptiNose

OptiNose ROCE

Delisted

The Return on Capital Employed (ROCE) of OptiNose (OPTN) as of Nov 11, 2026 is 10.49 %. In the previous year, Return on Capital Employed (ROCE) was 21.34 % — a change of -50.86% (lower).

ROCE

10.49 %

YoY

-50.86%

Last updated:

In 2024, OptiNose's return on capital employed (ROCE) was 10.49 %, a -50.86% increase from the 21.34 % ROCE in the previous year.

The OptiNose ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2017
-31.41 USD
Jan 1, 2018
-84.51 USD
Jan 1, 2019
-155.24 USD
Jan 1, 2020
-1,284.90 USD
Jan 1, 2021
305.21 USD
Jan 1, 2022
98.71 USD
Jan 1, 2023
21.34 USD
Jan 1, 2024
10.49 USD
The OptiNose ROCE history
YEARROCEYoY
10.49 %-50.86%
21.34 %-78.38%
98.71 %-67.66%
305.21 %-123.75%
-1,284.90 %+727.69%
-155.24 %+83.69%
-84.51 %+169.04%
-31.41 %-95.24%
-659.72 %-737.87%
103.43 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OptiNose Stock analysis

What does OptiNose do? OptiNose, Inc. develops and commercializes pharmaceutical products for ear, nose, and throat specialists and allergy specialists. The company's lead product, XHANCE (fluticasone propionate) nasal spray, uses a breath powered exhalation delivery system to treat chronic rhinosinusitis with nasal polyps. XHANCE is marketed as a topically acting anti-inflammatory corticosteroid that delivers medication directly to the site of inflammation. The company also has product candidates including XHANCE for chronic sinusitis, OPN-300, and OPN-021, which are part of its pipeline for ENT and allergy treatments. XHANCE is the company's primary revenue-generating product, targeting ENT and allergy specialists who prescribe it to patients with chronic rhinosinusitis and nasal polyps. The product's differentiated clinical profile positions it as a potential standard of care in its therapeutic area. Other pipeline products like OPN-300 and OPN-021 are in development but not yet commercialized, so they do not contribute to current revenue streams. The company's business model relies on the commercialization of XHANCE, which is sold to healthcare providers and patients through pharmaceutical distribution channels. ENT and allergy specialists are the key buyers of XHANCE, as it is designed specifically for their patient populations. The company's focus on nasal polyps and chronic sinusitis treatments aligns with the needs of these medical specialists. OptiNose is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling OptiNose's Return on Capital Employed (ROCE)

OptiNose's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing OptiNose's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

OptiNose's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in OptiNose’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about OptiNose stock

Return on Capital Employed (ROCE) of OptiNose is 10.49 % in 2024.

Return on Capital Employed (ROCE) of OptiNose changed from 21.34 % to 10.49 %, representing a -50.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) OptiNose since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s OptiNose with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — OptiNose

All Key Metrics — OptiNose